Tesamorelin: A Stabilized GHRH Analog
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) consisting of the GHRH(1-44) sequence with a trans-3-hexenoic acid modification at the N-terminus. This modification enhances metabolic stability while preserving full GHRHR agonist activity, making it a valuable research tool for studying GH-mediated biological processes.
GH/IGF-1 Axis Research
Tesamorelin has been investigated in preclinical models for GHRH-receptor-stimulated GH release. Research has examined whether this GH release influences lipid metabolism in animal models. These studies contribute to understanding the relationship between the GH/IGF-1 axis and metabolic regulation.
Comparison with Other GH Secretagogues
Compared with CJC-1295, tesamorelin retains the full GHRH(1-44) sequence versus CJC-1295's truncated (1-29) analog. Research comparing these compounds helps elucidate the structural requirements for optimal GHRHR activation and downstream GH release patterns.
Research Applications
Tesamorelin research also includes hepatic steatosis models and cardiovascular parameter assessment. Its well-characterized GHRH agonism makes it a useful reference compound for GH axis research. ROEHN supports GH axis research with CJC-1295/Ipamorelin.
Research Disclaimer
This article is for educational and informational purposes only. All compounds discussed are intended strictly for in-vitro and preclinical research use. They are not intended for human consumption. Always consult published scientific literature and institutional review requirements before initiating any research program.